Concepedia

Author

Ronald Rosenburg

University of Leeds

Also Known As

R Rosenburg, R. Rosenburg, Ronald Rosenburg, Rosenburg R, Rosenburg,Ronald

13

Publications

1.6K

Citations

9

H-Index

18

Concepts

All Affiliations

University of LeedsSanofi (France)Sanofi (United States)Grünenthal Group (Germany)Sanofi (Germany)
RR

About

Ronald Rosenburg is an author at University of Leeds specializing in medicine, pharmacotherapy, and clinical trials.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

43

2

Medicine

1

1

769

3

Applied Physiology

1

1

43

4

Exercise Physiology

1

1

43

5

Kinesiology

1

1

43

Ronald Rosenburg

×

9

Publications

1.6K

Citations

9

H-Index

YearCitations

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial

Josef S Smolen, Joachim R. Kalden, David L. Scott,

The Lancet

1999

769

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis

Paul Emery, FC Breedveld, E.‐M. Lemmel,

Lara D. Veeken

2000

469

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers

Maarten C. Kraan, Richard J. Reece, Ella C. Barg,

Arthritis & Rheumatism

2000

165

Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.

J. R. Kalden, D L Scott, J S Smolen,

PubMed

2001

53

Electromyography of lumbar erector spinae muscles — influence of posture, interelectrode distance, strength, and fatigue

Ronald Rosenburg, H. Seidel

European Journal of Applied Physiology

1989

43

Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure

Anne Paccaly, Annke Frick, Shashank Rohatagi,

The Journal of Clinical Pharmacology

2006

31

<p>Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients</p>

Derek Muse, Eva Tarau, Claudia Lefeber,

Journal of Pain Research

2019

22

<p>First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18</p>

Julia C. Finkel, J. Goldberg, Ronald Rosenburg,

Journal of Pain Research

2019

20

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

Anne Paccaly, Annke Frick, Marie‐Laure Ozoux,

The Journal of Clinical Pharmacology

2006

10

Page 1